arrow_back Trending Legislation
Share share

Accelerating Valley Fever Vaccine Development, Manufacturing, and National Registry

This Act authorizes funding and establishes a coordinated federal strategy to accelerate the development, licensing, and manufacturing of a human vaccine for Valley Fever (coccidioidomycosis) by 2034. The legislation aims to enhance public health security by pursuing effective protection against this fungal disease. It also creates a national registry to collect data and better track the disease's prevalence.
Key points
Establishes a National Strategy and appoints a Vaccine Coordinator to achieve the goal of having a licensed vaccine by 2034.
Authorizes $50 million in funding for grant and contract programs supporting research, clinical development, and initial manufacturing of the vaccine.
Creates the National Valley Fever Registry under the CDC to collect non-personal data on cases and improve disease monitoring.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
Valley Fever Awareness and Vaccine Development and Manufacturing Act of 2024
Print number: HR 9942
Sponsor: Rep. Duarte, John S. [R-CA-13]
Process start date: 2024-10-08
System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.
Summarized by: gemini-3-pro-preview
Source data: api.congress.gov
AI work logs for this document launch
Summary & Status

Key Questions about Accelerating Valley Fever Vaccine Development, Manufacturing, and National Registry

A structured overview of the legislative process, official sources, status and civic context.

What is the official ID of this bill?

The official print number for this legislation is HR 9942.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2024-10-08.

What are the main provisions?

Key points include:

  • Establishes a National Strategy and appoints a Vaccine Coordinator to achieve the goal of having a licensed vaccine by 2034.
  • Authorizes $50 million in funding for grant and contract programs supporting research, clinical development, and initial manufacturing of the vaccine.
  • Creates the National Valley Fever Registry under the CDC to collect non-personal data on cases and improve disease monitoring.

What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Duarte, John S. [R-CA-13].

What is the latest detailed status?

The latest detailed status is: Referred to the House Committee on Energy and Commerce.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-30.

Analysis and Potential Impact of HR 9942

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

CATEGORIES

Health